华润医药跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响

Core Viewpoint - China Resources Pharmaceutical (03320) experienced a nearly 3% decline in stock price, currently trading at HKD 4.46 with a transaction volume of HKD 25.16 million, following the profit forecast announcement from its subsidiary, China Resources Boya Biological (300294) [1] Group 1: Financial Performance - China Resources Boya Biological announced a profit forecast for the year ending December 31, 2025, estimating a net profit attributable to shareholders of approximately RMB 105 million to RMB 136.5 million, a significant decrease from the previous year's net profit of approximately RMB 397 million [1] - The forecast indicates an expected net loss attributable to shareholders, excluding non-recurring gains and losses, ranging from RMB 7.5 million to RMB 15 million, compared to a net profit of approximately RMB 302 million in the same period last year [1] Group 2: Business Challenges - The blood products business of China Resources Boya Biological is facing challenges due to factors such as expanded centralized procurement, DRG/DIP reforms, medical insurance cost control, and stringent regulation of reasonable drug use, leading to a reduction in clinical prescriptions and demand [1] - Increased market competition has resulted in a year-on-year decline in the gross profit margin of the blood products business during the reporting period [1]